The estimated Net Worth of Donald Robert Schemel is at least $169 millier dollars as of 4 October 2022. Donald Schemel owns over 200,000 units of Panbela Therapeutics stock worth over $168,929 and over the last 3 years Donald sold PBLA stock worth over $0.
Sign up
Donald Schemel PBLA stock SEC Form 4 insiders trading
Donald has made over 1 trades of the Panbela Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently Donald bought 200,000 units of PBLA stock worth $70,000 on 4 October 2022.
The largest trade Donald's ever made was buying 200,000 units of Panbela Therapeutics stock on 4 October 2022 worth over $70,000. On average, Donald trades about 66,667 units every 0 days since 2021. As of 4 October 2022 Donald still owns at least 482,654 units of Panbela Therapeutics stock.
You can see the complete history of Donald Schemel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Donald Schemel's mailing address?
Donald's mailing address filed with the SEC is 712 VISTA BLVD #305, , WACONIA, MN, 55387.
Insiders trading at Panbela Therapeutics
Over the last 4 years, insiders at Panbela Therapeutics have traded over $51,741 worth of Panbela Therapeutics stock and bought 406,888 units worth $0 . The most active insiders traders include Sachs Group Incgoldman Sach..., Donald Robert Schemel et Michael T. Cullen. On average, Panbela Therapeutics executives and independent directors trade stock every 67 days with the average trade being worth of $27,986. The most recent stock trade was executed by Sachs Group Incgoldman Sach... on 8 November 2023, trading 72,874 units of PBLA stock currently worth $51,741.
What does Panbela Therapeutics do?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
What does Panbela Therapeutics's logo look like?
Complete history of Donald Schemel stock trades at Panbela Therapeutics
Panbela Therapeutics executives and stock owners
Panbela Therapeutics executives and other stock owners filed with the SEC include:
-
Dr. Jennifer K. Simpson C.R.N.P., CRNP, M.S.N., Ph.D.,
CEO, Pres & Director -
Susan Horvath,
VP of Fin., CFO, Sec. & Treasurer -
Dr. Elizabeth Bruckheimer Ph.D.,
VP & Chief Scientific Officer -
Dr. Suzanne Gagnon,
Chief Medical Officer & Director -
Tammy Groene,
VP of Operations -
Dr. Thomas X. Neenan Ph.D.,
Co-Founder & Chief Scientific Officer -
Suzanne Gagnon,
Director -
Paul W. Schaffer,
Director -
Jeffrey S Mathiesen,
Director -
Susan Horvath,
V.P. of Finance & CFO -
Michael T. Cullen,
Director -
Jennifer K. Simpson,
President and CEO -
Donald Robert Schemel,
Director -
Arthur Fratamico,
Director -
Sachs Group Incgoldman Sach...,
-
Jeffrey E. Jacob,
Director -
Daniel Donovan,
Director